"Carboplatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An organoplatinum compound that possesses antineoplastic activity.
Concept/Terms
Carboplatin- Carboplatin
- cis-Diammine(cyclobutanedicarboxylato)platinum II
- CBDCA
Ribocarbo- Ribocarbo
- ribosepharm Brand of Carboplatin
Nealorin- Nealorin
- Prasfarma Brand of Carboplatin
Neocarbo- Neocarbo
- Neocorp Brand of Carboplatin
Paraplatin- Paraplatin
- Carboplat
- Paraplatine
- Bristol-Myers Squibb Brand of Carboplatin
Carbosin- Carbosin
- Pharmachemie Brand of Carboplatin
Carbotec- Carbotec
- Columbia Brand of Carboplatin
Ercar- Ercar
- Almirall Brand of Carboplatin
Platinwas- Platinwas
- Chiesi Brand of Carboplatin
Below are MeSH descriptors whose meaning is more general than "Carboplatin".
Below are MeSH descriptors whose meaning is more specific than "Carboplatin".
This graph shows the total number of publications written about "Carboplatin" by people in Harvard Catalyst Profiles by year, and whether "Carboplatin" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 1 | 4 | 5 |
| 1992 | 1 | 3 | 4 |
| 1993 | 3 | 4 | 7 |
| 1994 | 1 | 6 | 7 |
| 1995 | 3 | 6 | 9 |
| 1996 | 1 | 5 | 6 |
| 1997 | 1 | 6 | 7 |
| 1998 | 2 | 6 | 8 |
| 1999 | 2 | 5 | 7 |
| 2000 | 0 | 5 | 5 |
| 2001 | 3 | 8 | 11 |
| 2002 | 2 | 5 | 7 |
| 2003 | 0 | 12 | 12 |
| 2004 | 2 | 5 | 7 |
| 2005 | 4 | 15 | 19 |
| 2006 | 6 | 18 | 24 |
| 2007 | 4 | 6 | 10 |
| 2008 | 4 | 20 | 24 |
| 2009 | 4 | 16 | 20 |
| 2010 | 3 | 19 | 22 |
| 2011 | 3 | 23 | 26 |
| 2012 | 4 | 22 | 26 |
| 2013 | 2 | 14 | 16 |
| 2014 | 2 | 19 | 21 |
| 2015 | 7 | 15 | 22 |
| 2016 | 7 | 17 | 24 |
| 2017 | 5 | 11 | 16 |
| 2018 | 4 | 19 | 23 |
| 2019 | 4 | 18 | 22 |
| 2020 | 4 | 11 | 15 |
| 2021 | 1 | 3 | 4 |
Below are the most recent publications written about "Carboplatin" by people in Profiles.
-
Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations. Breast Cancer Res Treat. 2021 Oct; 189(3):641-651.
-
Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer. 2021 09; 159:56-65.
-
Procaspase-Activating Compound-1 Synergizes with TRAIL to Induce Apoptosis in Established Granulosa Cell Tumor Cell Line (KGN) and Explanted Patient Granulosa Cell Tumor Cells In Vitro. Int J Mol Sci. 2021 Apr 29; 22(9).
-
TORC1/2 kinase inhibition depletes glutathione and synergizes with carboplatin to suppress the growth of MYC-driven medulloblastoma. Cancer Lett. 2021 04 28; 504:137-145.
-
Cisplatin-Mediated Upregulation of APE2 Binding to MYH9 Provokes Mitochondrial Fragmentation and Acute Kidney Injury. Cancer Res. 2021 02 01; 81(3):713-723.
-
Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases. Breast Cancer Res. 2020 11 30; 22(1):131.
-
Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. J Thorac Oncol. 2021 01; 16(1):162-168.
-
Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma. Future Oncol. 2021 Feb; 17(5):611-627.
-
Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells. Gynecol Oncol. 2020 12; 159(3):869-876.
-
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2020 09 24; 383(13):1218-1230.